Skip to main content

What Animal Models are Useful in Selecting New Antiarrhythmic Drugs?

  • Chapter

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 47))

Abstract

Although many animal models are useful for evaluating new antiarrhythmic agents, it must be admitted that no animal model is ideal, nor can any single animal model alone predict antiarrhythmic efficacy in man. The selection of which animal model(s) to use depends first of all on whether one is “screening” for a new active compound or alternatively, “evaluating” an already identified active antiarrhythmic drug. This paper will deal primarily with models designed to evaluate mechanisms of action and effectiveness of new antiarrhythmic agents.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Moore EN and Spear JF: Acute animal models for the study of antiarrhythmic drugs for the prevention of sudden coronary death. In: Clinical Pharmacology of Antiarrhythmic Therapy. Ed. Lucchesi, BR, Dingell, JV and Schwarz RP Jr. Raven Press, N.Y. pp. 31–46, 1984.

    Google Scholar 

  2. Wiggers, CJ, and Wegria R: Ventricular fibrillation due to a single localized induction and condenser shock applied during the vulnerable phase of ventricular systole. Am. J. Physiol. 128: 500–505.

    Google Scholar 

  3. Euler DE and Moore EN: Continuous fractionated electrical activity after stimulation of the ventricles during the vulnerable period: evidence for local reentry. Am. J. Cardiol. 46: 783–791, 1980.

    Article  PubMed  CAS  Google Scholar 

  4. Han J: Ventricular vulnerability during acute coronary occlusion. Am. J Cardiol. 24: 857–864, 1969.

    Article  PubMed  CAS  Google Scholar 

  5. Greenberg, HM and Dwyer, EM. Eds. Sudden Coronary Death Ann. NY Acad. Sci. 382: 1–484, 1982.

    Google Scholar 

  6. Kaplinsky, E, Ogawa S, Balke CW and Dreifus LS: Two periods of early ventricular arrhythmia in the canine acute myocardial infarction model. Circ. 60: 397–403, 1979.

    CAS  Google Scholar 

  7. Harris, AS and Rojas, AG: Initiation of ventricular fibrillation due to coronary occlusion. Exp. Med. Surg. 1: 105–122, 1943.

    Google Scholar 

  8. Moore, EN, Spear, JF, Feldman HS and Moller R: Electrophysiological properties of a new antiarrhythmic drug — Tocainide. Am. J. Cardiol. 41: 703–708, 1978.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Moore, E.N., Spear, J.F. (1985). What Animal Models are Useful in Selecting New Antiarrhythmic Drugs?. In: Morganroth, J., Moore, E.N. (eds) Cardiac Arrhythmias: New Therapeutic Drugs and Devices. Developments in Cardiovascular Medicine, vol 47. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2595-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2595-6_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9626-3

  • Online ISBN: 978-1-4613-2595-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics